spironolactone has been researched along with Coronary Restenosis in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 8.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| " The Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS) with eplerenone in patients who were post-myocardial infarction underscores the additive benefit of such a strategy in post-infarction patients that typify an at-risk population for recurrent cardiovascular events." | 4.82 | Eplerenone: will it have a role in the treatment of acute coronary syndromes? ( Meier, DJ; Pitt, B; Rajagopalan, S, 2004) |
| " Aldosterone itself has been shown to increase cardiovascular fibrosis, therefore, we studied the suppressive effects of eplerenone, a new aldosterone receptor antagonist, on neointimal hyperplasia after coronary stent implantation in swine." | 3.73 | Eplerenone suppresses neointimal formation after coronary stent implantation in swine. ( Iso, Y; Katagiri, T; Sato, T; Suzuki, H; Takeyama, Y; Wakabayashi, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meier, DJ | 1 |
| Pitt, B | 1 |
| Rajagopalan, S | 1 |
| Kursaklioglu, H | 2 |
| Iyisoy, A | 2 |
| Amasyali, B | 1 |
| Celik, T | 2 |
| Ozturk, C | 1 |
| Kose, S | 1 |
| Isik, E | 2 |
| Wakabayashi, K | 1 |
| Suzuki, H | 1 |
| Sato, T | 1 |
| Iso, Y | 1 |
| Katagiri, T | 1 |
| Takeyama, Y | 1 |
1 review available for spironolactone and Coronary Restenosis
| Article | Year |
|---|---|
Eplerenone: will it have a role in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Collagen; Coronary Restenosis; Eplerenone; Humans; | 2004 |
1 trial available for spironolactone and Coronary Restenosis
| Article | Year |
|---|---|
Spironolactone does not prevent restenosis after coronary stenting in humans.
Topics: Adult; Aged; Coronary Restenosis; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2004 |
2 other studies available for spironolactone and Coronary Restenosis
| Article | Year |
|---|---|
Eplerenone suppresses neointimal formation after coronary stent implantation in swine.
Topics: Actins; Administration, Oral; Animals; Blood Vessel Prosthesis Implantation; Collagen Type I; Collag | 2006 |
Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans?
Topics: Angioplasty, Balloon, Coronary; Animals; Collagen; Coronary Restenosis; Disease Models, Animal; Eple | 2007 |